About Our Team
Applying breakthrough science to develop innovative, clinically-impactful vaccines for people in need around the world
Matrivax is a biotechnology company developing human vaccines for the prevention and treatment of life-threatening infectious diseases.
Our pipeline includes two vaccine candidates implementing proprietary protective antigens against Streptococcus pneumoniae (MVX01) and Clostridioides difficile (MVX02).
Matrivax is a privately-held company funded by Morningside Investments and based in the biotech hub of Boston, MA.